SCHEMBL1420531

SCHEMBL1420531

[CH]c1cccc(OC)c1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ NFE2L2 Q16236 7/20 0.48
▸ CA12 O43570 2/20 0.48
▸ CA1 P00915 2/20 0.48
▸ CA2 P00918 2/20 0.48
▸ CA14 Q9ULX7 2/20 0.48
▸ CA4 P22748 1/20 0.48
▸ CA7 P43166 1/20 0.48
▸ CA9 Q16790 1/20 0.48
▸ CYP19A1 P11511 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ ALOX12 P18054 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2097234 1.00 SMN1; SMN2 (0.50) SMN1; SMN2NFE2L2CA12CA1CA2
SCHEMBL25434306 0.82 CA1 (0.61) SMN1; SMN2NFE2L2CA12CA1CA2
SCHEMBL151213 0.82 CA1 (0.61) SMN1; SMN2NFE2L2CA12CA1CA2
SCHEMBL27753904 0.82 CA1 (0.61) SMN1; SMN2NFE2L2CA12CA1CA2
Cyanide SCHEMBL31190156 0.80 SMN1; SMN2 (0.54) SMN1; SMN2NFE2L2CA12CA1CA2
Hydrochloric Acid SCHEMBL31658961 0.79 SMN1; SMN2 (0.58) SMN1; SMN2NFE2L2CA12CA1CA2
Bromide SCHEMBL28158222 0.79 SMN1; SMN2 (0.58) SMN1; SMN2NFE2L2CA12CA1CA2
SCHEMBL27731704 0.79 SMN1; SMN2 (0.58) SMN1; SMN2NFE2L2CA12CA1CA2
Ammonia Solution, Strong SCHEMBL4268652 0.79 SMN1; SMN2 (0.58) SMN1; SMN2NFE2L2CA12CA1CA2
SCHEMBL1571609 0.78 CYP1A1 (0.40) SMN1; SMN2CA12CA1CA2CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2858649-B1 TREATMENT OF MOTOR AND MOVEMENT DISORDER SIDE EFFECTS ASSOCIATED WITH PARKINSON'S DISEASE TREATMENTS PSYCHOGENICS INC (US) 2019-10-23 — — EP claimed
EP-1854799-B1 Process for the preparation of a taxane derivative INDENA SPA (IT) 2011-04-27 — — EP claimed
US-RE40901-E1 Taxane derivatives and processes for the preparation thereof INDENA S.P.A. (IT) 2009-09-01 — — US claimed
WO-2007131601-A1 A PROCESS FOR THE PREPARATION OF A TAXANE DERIVATIVE INDENA S.P.A. (IT) 2007-11-22 — — WO claimed
EP-1854799-A1 Process for the preparation of a taxane derivative INDENA S.p.A. (IT) 2007-11-14 — — EP claimed
US-7232916-B1 Process for the preparation of a taxane derivative INDENA S.P.A. (IT) 2007-06-19 — — US claimed
EP-1192162-B1 TAXANE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF INDENA SPA (IT) 2004-09-29 — — EP claimed
EP-1347984-B1 A PROCESS FOR THE PREPARATION OF TAXAN DERIVATIVES INDENA SPA (IT) 2004-09-01 — — EP claimed
US-6737534-B2 USING 10-DEACETYLBACCATINE III EASILY RECOVERED IN LARGE AMOUNTS FROM TAXUS BACCATA LEAVES AS STARTING MATERIAL INDENA S.P.A. (IT) 2004-05-18 — — US claimed
US-20040030164-A1 Process for the preparation of taxan derivatives IDENA S.P.A. (IT) 2004-02-12 — — US claimed
EP-1347984-A2 A PROCESS FOR THE PREPARATION OF TAXAN DERIVATIVES INDENA S.p.A. (IT) 2003-10-01 — — EP claimed
WO-2002044161-A2 A PROCESS FOR THE PREPARATION OF TAXAN DERIVATIVES INDENA S.P.A. (IT) 2002-06-06 — — WO claimed
EP-1192162-A2 TAXANE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF INDENA S.p.A. (IT) 2002-04-03 — — EP claimed
WO-2001002407-A2 TAXANE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF INDENA S.P.A. (IT) 2001-01-11 — — WO claimed
WO-2024145435-A2 LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS Life Technologies Corporation (US) 2024-07-04 — — WO disclosed
CN-116870157-A Composition for improving skin disorders 日本乐敦制药株式会社 2023-10-13 — — CN disclosed
CN-107474514-B Photocurable fluoropolyether rubber composition, cured product thereof, and method for suppressing foaming of cured product of fluoropolyether rubber during closed curing 信越化学工业株式会社 2021-10-26 — — CN disclosed
WO-2002044161-A2 A PROCESS FOR THE PREPARATION OF TAXAN DERIVATIVES INDENA S.P.A. (IT) 2002-06-06 — — WO disclosed
EP-1192162-A2 TAXANE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF INDENA S.p.A. (IT) 2002-04-03 — — EP disclosed
WO-2001002407-A2 TAXANE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF INDENA S.P.A. (IT) 2001-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040030164-A1 Process for the preparation of taxan derivatives COX14, SFN, NCDN SMN1; SMN2 376/4885NFE2L2 4409/4885CA12 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback